Practice Signal

KRAS Inhibitors in Pancreatic Cancer

This review helps pharmacists understand how daraxonrasib supersedes the earlier KRAS G12C-only agents in pancreatic cancer and how to manage its rash-dominant toxicity, drug interactions, and molecular-testing prerequisites.

State of Play

Metastatic pancreatic ductal adenocarcinoma (mPDAC) has long been considered undruggable at KRAS, with no single standard second-line regimen beyond fluoropyrimidine- or gemcitabine-based cytotoxic chemotherapy. The first wave of covalent KRAS G12C inhibitors (sotorasib, adagrasib) proved that direct KRAS inhibition was feasible but reached only the 1 to 2% of patients carrying that allele, leaving the dominant G12D and G12V variants untargeted. Pan-RAS inhibition now addresses that majority.

What Changed

The randomized phase 3 RASolute 302 trial (PMID 42223072) showed that oral daraxonrasib, a RAS(ON) inhibitor active across G12 variants, reduced the risk of death by 60% (HR 0.40) and doubled median overall survival (OS) to 13.2 versus 6.6 months against chemotherapy, with concordant progression-free survival (PFS), objective response rate (ORR), and patient-reported outcome benefits. This is a categorical shift from the earlier single-arm G12C data (sotorasib ORR 21%, adagrasib pancreatic ORR 33%), which established proof of concept but never demonstrated a randomized survival benefit.

How It Fits the Guidelines

Current National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) guidelines establish no single standard second-line mPDAC regimen and list KRAS G12C inhibitors only as a category option for that rare subgroup based on single-arm data. The RASolute 302 result is not yet reflected in guidelines and creates tension: a molecularly targeted therapy now shows a large-magnitude randomized benefit for the RAS G12 majority, which the guideline framework does not yet accommodate. Pharmacists should expect NCCN and ESMO revision as regulatory review proceeds.

Evidence at a Glance

Practice Considerations

• Confirm RAS mutational status (KRAS, NRAS, and HRAS at codons 12, 13, and 61) via broad next-generation sequencing before therapy selection, since both the rare G12C subset (sotorasib, adagrasib) and the far larger G12/G12D/G12V population (daraxonrasib) are missed by targeted single-gene testing.
• Build proactive dermatologic and gastrointestinal supportive-care plans for daraxonrasib, since rash affects roughly 85 to 90% of patients and is the leading cause of dose reduction; early topical glucocorticoids, systemic tetracyclines, and antidiarrheals support an interrupt-and-resume strategy that preserved relative dose intensity above 86% across trials.
• Counsel that daraxonrasib toxicity is on-target and dominated by dermatologic and gastrointestinal effects rather than the myelosuppression seen with cytotoxic chemotherapy, and that its once-daily 300 mg oral form shifts management to the outpatient setting with attendant adherence support.
• Screen for CYP3A4 inhibitors and inducers and potential OATP1B1/OATP1B3-mediated interactions with daraxonrasib, since preclinical work identifies human CYP3A4 metabolism and hepatic OATP uptake as exposure determinants; recognize that ABCB1 efflux at the blood-brain barrier may limit central nervous system activity.
• For the 1 to 2% of patients with KRAS G12C, retain sotorasib and adagrasib as tolerable off-label options while monitoring for QT prolongation and reviewing concomitant QT-prolonging agents and electrolytes with adagrasib, and intensify liver function monitoring if G12C inhibitors are combined with checkpoint blockade given reported hepatotoxicity.
• Prepare operationally for imminent daraxonrasib-based combination trials (with chemotherapy, cetuximab, and eventually PD-1 or PD-L1 agents), noting that pan-RAS and RAS(ON) agents block wild-type RAS in T cells and carry theoretical additive toxicity when combined with immunotherapy, unlike allele-specific inhibitors.

Open Questions

• Will the RASolute 302 survival benefit hold with mature follow-up given the open-label design and currently immature data?
• Do efficacy and toxicity differ meaningfully across individual RAS variants (G12D versus G12V versus G12R), which the single-arm data could not resolve?
• Can the preclinical rationale for combining RAS inhibition with PD-1 blockade and CD40 agonists translate into durable human benefit, and at what added toxicity cost?
• How will clinically meaningful CYP3A4 and OATP drug interactions and ABCB1-limited brain penetration manifest in humans, and what monitoring or dose adjustment will be required?

← Back to Evidence Rounds